

Table 6.6h
Persistency of Discharge Regimen by Follow-up Period, 2002 to 2006
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant				
	2002	2003	2004	2005	2006
Discharge Regimen (w/ or w/o Steroid Use)					
CyA+MMF					
At Discharge (N)	4	2	1	-	2
At Discharge (%)	100.0%	100.0%	100.0%	-	100.0%
6 Months PostTx (%)	50.0%	100.0%	100.0%	-	0.0%
1 Year PostTx (%)	50.0%	100.0%	100.0%	-	0.0%
2 Years PostTx (%)	25.0%	50.0%	100.0%	-	0.0%
3 Years PostTx (%)	0.0%	0.0%	100.0%	-	0.0%
CyA+Siro					
At Discharge (N)	1	1	1	-	1
At Discharge (%)	100.0%	100.0%	100.0%	-	100.0%
6 Months PostTx (%)	100.0%	100.0%	-	-	100.0%
1 Year PostTx (%)	100.0%	-	-	-	100.0%
2 Years PostTx (%)	100.0%	-	-	-	-
3 Years PostTx (%)	0.0%	-	-	-	-
Siro+MMF					
At Discharge (N)	-	1	-	2	-
At Discharge (%)	-	100.0%	-	100.0%	-
6 Months PostTx (%)	-	100.0%	-	100.0%	-
1 Year PostTx (%)	-	100.0%	-	100.0%	-
2 Years PostTx (%)	-	100.0%	-	0.0%	-
3 Years PostTx (%)	-	0.0%	-	0.0%	-
Tac+Aza					
At Discharge (N)	1	-	2	-	-
At Discharge (%)	100.0%	-	100.0%	-	-
6 Months PostTx (%)	100.0%	-	100.0%	-	-
1 Year PostTx (%)	0.0%	-	100.0%	-	-
2 Years PostTx (%)	0.0%	-	50.0%	-	-
3 Years PostTx (%)	0.0%	-	-	-	-
Tac+MMF					
At Discharge (N)	84	61	61	91	61
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	82.1%	86.9%	78.3%	89.9%	85.2%
1 Year PostTx (%)	67.7%	75.2%	70.0%	84.2%	76.1%
2 Years PostTx (%)	60.4%	55.1%	61.5%	72.6%	-
3 Years PostTx (%)	52.9%	48.5%	48.3%	72.6%	-
Tac+Siro					
At Discharge (N)	15	18	13	18	17
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	86.7%	66.7%	84.6%	77.8%	82.4%

(Continued)

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

Table 6.6h (Continued)
Persistency of Discharge Regimen by Follow-up Period, 2002 to 2006
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant				
	2002	2003	2004	2005	2006
Discharge Regimen (w/ or w/o Steroid Use)					
Tac+Siro					
1 Year PostTx (%)	80.0%	61.1%	61.5%	72.2%	34.0%
2 Years PostTx (%)	65.5%	50.0%	46.2%	50.0%	-
3 Years PostTx (%)	56.1%	43.8%	46.2%	-	-

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.